Special Clinical Focus
- Allogenic stem cell transplantation
- Autologous stem cell transplantation
- Lymphoma Centre
- Antibody therapy
- DKMS stem cell donation
Stem cell transplantation plays an important role in the treatment of malignant conditions in Hamburg. So, over 180 patients per year are given a stem cell transplant at the Haematology-Oncology Centre in Hamburg. Over 1,000 patients are admitted for treatment and over 15,000 patients are treated as out-patients at the Department of Haematology in Hamburg.
For many patients, the Department of Stem Cell Transplantation in Hamburg is an important therapeutic option for the treatment of, for example, leukaemia or multiple myeloma. Here, either autologous stem cells (so-called autologous stem cell transplantation) or exogenous stem cells (so-called autologous stem cell transplantation) are transplanted by the leukaemia specialist in Hamburg, Prof. Schmitz.
The Department of Haematology in Hamburg also performs stem cell transplantation within the framework of clinical studies for patients with malignant lymphomata so that the leukaemia specialist in Hamburg can offer treatment in accordance with the current insights in medicine. With over 180 transplants per year, the Department of Stem Cell Transplantation in Hamburg is among the largest centres in Germany. Chemotherapy is still an important therapeutic option in the treatment of malignant conditions. While previously the chemotherapy medications killed off all proliferating cells without distinction, today, substances (such as antibodies) are increasingly utilised, which are intended to destroy only tumour cells in a targeted fashion. All up to date chemotherapy techniques are performed at the Department of Haematology in Hamburg. Hence, several thousand patients are given chemotherapy or immunotherapy annually by the leukaemia specialist in Hamburg.
The leukaemia specialist in Hamburg is able to draw on an in-house specialist haematology diagnostics laboratory. Here, haematological conditions are diagnosed by means of highly specialised examinations. So, for example, even the smallest quantities of tumour cells can be detected using flow cytometry (FACS laboratory), which is important for the primary diagnosis, on the one hand, as well as for the therapeutic and follow-up control of the cancer condition. The specialist Departments of Nuclear Medicine and Radiotherapy, Oncology, Stem Cell Transplantation and Haematology are combined at the Haematology-Oncology Centre in Hamburg. As a result, the diagnosis and treatment can be undertaken at the highest medical level, with the involvement of the respective specialists.
The clinical focus of the Department is the treatment of all forms of non-Hodgkin’s lymphoma and of Hodgkin's disease. The head of the Department is the co-chairman of the German Highly Malignant non-Hodgkin’s Lymphoma Study Group (DSHNHL), one of the largest study groups worldwide, which is concerned with all aspects of the diagnosis and treatment of lymphomata. The DSHNHL has influenced the current treatment standards for lymphomata decisively; publications appear regularly in prestigious international journals; members of staff of the Department give presentations at national and international conferences.
The research focus of the Department is the treatment of patients with recurrent or refractory conditions of the lymph nodes, which do not respond to conventional treatment. In such cases, new and complex therapeutic techniques are employed, such as autologous and allogenic stem cell transplantation, radioimmunotherapy and treatment with medications which specifically attack the tumour (targeted therapy) or not yet approved substances within the framework of clinical trials. Innovative therapeutic concepts including transplantation are also utilised for patients with acute and chronic leukaemias (e.g. chronic lymphatic leukaemia).
of selected experts in the specialist field Oncology / Hematology